- Home
- CBUS vs AGEN Comparison
CBUS vs AGEN Comparison
Compare CBUS & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBUS
- AGEN
- Stock Information
- Founded
- CBUS 2010
- AGEN 1994
- Country
- CBUS United States
- AGEN United States
- Employees
- CBUS N/A
- AGEN N/A
- Industry
- CBUS Agricultural Chemicals
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CBUS Industrials
- AGEN Health Care
- Exchange
- CBUS Nasdaq
- AGEN Nasdaq
- Market Cap
- CBUS 120.1M
- AGEN 96.2M
- IPO Year
- CBUS 2017
- AGEN 2000
- Fundamental
- Price
- CBUS $3.69
- AGEN $2.99
- Analyst Decision
- CBUS Strong Buy
- AGEN Buy
- Analyst Count
- CBUS 3
- AGEN 3
- Target Price
- CBUS $22.83
- AGEN $10.50
- AVG Volume (30 Days)
- CBUS 107.9K
- AGEN 551.7K
- Earning Date
- CBUS 11-07-2024
- AGEN 11-12-2024
- Dividend Yield
- CBUS N/A
- AGEN N/A
- EPS Growth
- CBUS N/A
- AGEN N/A
- EPS
- CBUS N/A
- AGEN N/A
- Revenue
- CBUS $4,152,999.00
- AGEN $160,427,000.00
- Revenue This Year
- CBUS $99.17
- AGEN N/A
- Revenue Next Year
- CBUS $67.09
- AGEN $36.13
- P/E Ratio
- CBUS N/A
- AGEN N/A
- Revenue Growth
- CBUS 449.34
- AGEN 59.00
- 52 Week Low
- CBUS $2.86
- AGEN $2.50
- 52 Week High
- CBUS $23.18
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- CBUS 42.55
- AGEN 41.32
- Support Level
- CBUS $3.68
- AGEN $2.73
- Resistance Level
- CBUS $4.24
- AGEN $3.85
- Average True Range (ATR)
- CBUS 0.40
- AGEN 0.29
- MACD
- CBUS -0.07
- AGEN -0.01
- Stochastic Oscillator
- CBUS 8.59
- AGEN 24.03
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).